RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group - Gilde Healthcare

RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group

19 January 2021

Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group.

Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in and around Lahnstein and provide imaging services to several local hospitals.

RAD-x is pleased to see its Partnership model confirmed by the integration of RZL and expects to further accelerate the growth of its platform structure in 2021.

 

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over $1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, MedTech and therapeutics. The venture & growth companies are based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare Private Equity as part of Investor Consortium acquires DETAX

Specialist for medical polymer materials DETAX resolves ownership succession in the course of a management buy-out and continues its successful growth track together with a strong Investor Consortium DETAX is a leading global supplier of...
3 December 2021

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Adcendo, a biotech company focused on the development of...
1 December 2021

Gilde Healthcare company Sanifit acquired by Vifor Pharma

Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor...
22 November 2021